Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
S Vafaei, AO Zekiy, RA Khanamir, BA Zaman… - Cancer Cell …, 2022 - Springer
Recently, immune checkpoint inhibitors (ICIs) therapy has become a promising therapeutic
strategy with encouraging therapeutic outcomes due to their durable anti-tumor effects …
strategy with encouraging therapeutic outcomes due to their durable anti-tumor effects …
[HTML][HTML] Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?
S Demaria, C Guha, J Schoenfeld, Z Morris… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Recent evidence indicates that ionizing radiation can enhance immune responses to
tumors. Advances in radiation delivery techniques allow hypofractionated delivery of …
tumors. Advances in radiation delivery techniques allow hypofractionated delivery of …
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous …
JD Schoenfeld, A Giobbie-Hurder… - The Lancet …, 2022 - thelancet.com
Background Patients with non-small-cell lung cancer (NSCLC) that is resistant to PD-1 and
PD-L1 (PD [L]-1)-targeted therapy have poor outcomes. Studies suggest that radiotherapy …
PD-L1 (PD [L]-1)-targeted therapy have poor outcomes. Studies suggest that radiotherapy …
Assessing the interactions between radiotherapy and antitumour immunity
C Grassberger, SG Ellsworth, MQ Wilks… - Nature reviews Clinical …, 2019 - nature.com
Immunotherapy, specifically the introduction of immune checkpoint inhibitors, has
transformed the treatment of cancer, enabling long-term tumour control even in individuals …
transformed the treatment of cancer, enabling long-term tumour control even in individuals …
A review on lymphocyte radiosensitivity and its impact on radiotherapy
H Paganetti - Frontiers in Oncology, 2023 - frontiersin.org
It is well known that radiation therapy causes lymphopenia in patients and that this is
correlated with a negative outcome. The mechanism is not well understood because …
correlated with a negative outcome. The mechanism is not well understood because …
The influence of severe radiation-induced lymphopenia on overall survival in solid tumors: a systematic review and meta-analysis
PJJ Damen, TE Kroese, R van Hillegersberg… - International Journal of …, 2021 - Elsevier
Purpose Emerging evidence suggests a detrimental prognostic association between
radiation-induced lymphopenia (RIL) and pathologic response, progression-free survival …
radiation-induced lymphopenia (RIL) and pathologic response, progression-free survival …
Rational combinations of immunotherapy with radiotherapy in ovarian cancer
FG Herrera, M Irving, LE Kandalaft, G Coukos - The Lancet Oncology, 2019 - thelancet.com
Except for its use in palliative care, radiotherapy has been largely abandoned in the
management of ovarian cancer because of the recognised efficacy and lower toxicity of …
management of ovarian cancer because of the recognised efficacy and lower toxicity of …
Ultra high dose rate (35 Gy/sec) radiation does not spare the normal tissue in cardiac and splenic models of lymphopenia and gastrointestinal syndrome
BP Venkatesulu, A Sharma, JM Pollard-Larkin… - Scientific reports, 2019 - nature.com
Recent reports have shown that very high dose rate radiation (35–100 Gy/second) referred
to as FLASH tends to spare the normal tissues while retaining the therapeutic effect on …
to as FLASH tends to spare the normal tissues while retaining the therapeutic effect on …
A randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation for patients with metastatic colorectal cancer
AM Monjazeb, A Giobbie-Hurder, A Lako… - Clinical Cancer …, 2021 - AACR
Purpose: Prospective human data are lacking regarding safety, efficacy, and immunologic
impacts of different radiation doses administered with combined PD-L1/CTLA-4 blockade …
impacts of different radiation doses administered with combined PD-L1/CTLA-4 blockade …
Impact of radiation dose to the host immune system on tumor control and survival for stage III non-small cell lung cancer treated with definitive radiation therapy
CJ Ladbury, CG Rusthoven, DR Camidge… - International Journal of …, 2019 - Elsevier
Purpose The significance of radiation dose to the host immune system during the treatment
of stage III non-small cell lung cancer (NSCLC) is unknown, but higher doses were …
of stage III non-small cell lung cancer (NSCLC) is unknown, but higher doses were …